

J. B. CHEMICALS & PHARMACEUTICALS LIMITED

27 April 2020

BSE Ltd. Phiroze Jeejeebhoy Towers Dalal Street Mumbai 400 001

BSE Scrip Code: 506943

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: ANDA approval by US FDA

This is to inform you that US FDA has approved Company's Abbreviated New Drug Application (ANDA) for Carbamazepine Extended Release Tablets USP 100 mg, 200 mg and 400 mg. (for treatment of Epilepsy and Trigeminal Neuralgia). The product is a generic version of Tegretol XR tablet in the same strength of Novartis Pharmaceuticals Corp. According to IQVIA, US sales were approximately USD 128 million.

The Company plans to commercialize this product in Q3 of this financial year and is expected to boost the Company's US sales.

This letter is being submitted without signature due to constraints of work from home consequent to ongoing national lockdown. Hence, we request you to take this announcement on record based on Sd/-mode.

Thanking you,

Yours faithfully,

For J. B. Chemicals & Pharmaceuticals Limited

Sd/

M. C. Mehta Company Secretary & Vice President - Compliance

 Registered Office: Neelam Centre, B Wing, 4th Floor Hind Cycle Road, Worli Mumbai - 400 030 Corporate Office: Cnergy IT Park Unit A2, 3rd Floor, Unit A, 8th Floor Appa Saheb Marathe Marg, Prabhadevi Mumbai - 400 025 +91 22 2439 5200 / 2439 5500
+91 22 2431 5331 / 2431 5334
info@jbcpl.com
www.jbcpl.com

CIN: L24390MH1976PLC019380